Frequency and characteristics of <scp>chemotherapy‐associated</scp> thrombotic microangiopathy: Analysis from a large pharmacovigilance database
Nattawat Klomjit, Richard B. Evans, Thomas K. Le, Sophia L. Wells, Jessica Ortega, Olivia Green‐Lingren, Marshall Mazepa, Meghan E. Sise, Kenar D. Jhaveri, Shruti Gupta
Abstract
We used the information component (IC), a disproportionate Bayesian analysis comparing the number of observed versus expected adverse drug reactions, to determine the potential association between anti-neoplastic agents and thrombotic microangiopathy (TMA). The IC025 indicates the lower end of 95% of IC, in which a value >0 suggests a disproportionality signal between the drug of interest and the adverse drug reaction. Carfilzomib had the highest IC025 for TMA among all studied chemotherapies followed by gemcitabine, mitomycin, bevacizumab, and bortezomib.
Topics & Concepts
PharmacovigilanceThrombotic microangiopathyMedicineBevacizumabOncologyAdverse effectInternal medicineAdverse Event Reporting SystemGemcitabinePharmacologyDrugDatabaseChemotherapyComputer scienceDiseaseComplement system in diseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaRenal Transplantation Outcomes and Treatments